IMV EBITDA
What is the EBITDA of IMV?
The EBITDA of IMV, Inc. is -$43.81
What is the definition of EBITDA?
EBITDA is a company’s earnings before interest, taxes, depreciation, and amortization and is an accounting measure calculated using a company’s net earnings, before interest expenses, taxes, depreciation and amortization are subtracted, as a proxy for a company’s current operating profitability.
ttm (trailing twelve months)
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA of companies in the Health Care sector on TSX compared to IMV
What does IMV do?
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Companies with ebitda similar to IMV
- Porch has EBITDA of -$44.24
- Hybrid Kinetic has EBITDA of -HKD$44.24
- Spruce Biosciences has EBITDA of -$44.24
- Paratek Pharmaceuticals has EBITDA of -$44.24
- Sino Prosper () has EBITDA of -HKD$44.07
- Enthusiast Gaming has EBITDA of -CAD$43.96
- IMV has EBITDA of -$43.81
- ABIVAX Societe Anonyme has EBITDA of -€43.78
- Abivax SA has EBITDA of -€43.78
- mCloud Technologies has EBITDA of -CAD$43.66
- China Parenting Network has EBITDA of -¥43.63
- SKIL Infrastructure has EBITDA of -₨43.55
- GMP Capital has EBITDA of -CAD$43.53